Results 161 to 170 of about 27,659 (185)

Novel Antithrombotics in Geriatric PCI for STEMI: Balancing Ischemic Protection with Bleeding Risk: Short title: Novel Antithrombotics in Geriatric PCI for STEMI. [PDF]

Galen Med J
Pakizeh I, Sohrabi B.
europepmc   +1 more source

Antithrombotic Strategies After Complex Percutaneous Coronary Intervention. [PDF]

J Clin Med
Ueki Y, Kuwahara K.
europepmc   +1 more source

Subacute Stent Thrombosis Associated With Prasugrel Refractoriness in a Patient With Chronic ITP. [PDF]

JACC Case Rep
Takeo M, Okabe H, Hidaka K, Naka Y, Setoyama K, Kataoka M.   +5 more
europepmc   +1 more source

P2Y12-P-selectin-mediated platelet activation in a murine model of dengue-associated thrombocytopenia. [PDF]

EBioMedicine
Batista VL, Martins JR, Dias ASL, Fonseca TCM, Silva LS, Rocha FEO, Costa PAC, Silva WN, Pereira JAB, Silva AT, Canalis ML, Antunes M, Guimarães PPG, Menezes GB, Sabino AP, Sousa LP, Queiroz-Junior CM, Hottz ED, Teixeira MM, Costa VV.   +19 more
europepmc   +1 more source

Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors. [PDF]

Eur Heart J Acute Cardiovasc Care
Gelbenegger G, Lipa AJ, Jorda A, Zilberszac R, Heinz G, Staudinger T, Zauner C, Holzer M, Friedrich G, Plank F, Lang IM, Jilma B, Siller-Matula JM.   +12 more
europepmc   +1 more source

Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function

Thrombosis and Haemostasis, 2010
The thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention. However, the optimal level of P2Y12 blockade to effectively inhibit platelet function
Robert Buckland, Robert F. Storey, Heather M Judge   +2 more
exaly   +2 more sources

International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies

Circulation, 2017
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability
Dominick Angiolillo, Francesco Franchi
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD

Cancer Cell, 2022
Long-Jun Wu, Justin McCallen, Jay A Berzofsky   +2 more
exaly  

P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition

Molecular Therapy, 2022
Patrick Ming-Kuen Tang, Anping Xu, Hui Y Lan   +2 more
exaly